Stage IIIB Lung Non-Small Cell Cancer AJCC v7 Recruiting Phase 1 Trials for Navitoclax (DB12340)

IndicationStatusPhase
DBCOND0115716 (Stage IIIB Lung Non-Small Cell Cancer AJCC v7)Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02520778Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung CancerTreatment